$13.68
Value $3.0B
ADMA and TMO stock compared: price, dividend, valuation and results, from SEC filings.
$13.68
Value $3.0B
$700.22
Value $260B
ADMA Biologics (ADMA) has a market value of $3.0B and Thermo Fisher Scientific (TMO) $260B. Over the last year, with dividends, ADMA moved -16.9% and TMO +19.5%. The P/E is 16.6 for ADMA and 36.8 for TMO. Dividend yield: ADMA none, TMO 0.26%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
ADMA$3.0B
TMO$260B
TMO is 86 times ADMA
Revenue, 12 months
ADMA$519M
TMO$47.4B
TMO is 91 times ADMA
Net income, 12 months
ADMA$182M
TMO$7.1B
TMO is 39 times ADMA
Operating margin
ADMA46.5%
TMO17.9%
28.6 points apart
ROIC
ADMA32.6%
TMO8.2%
24.4 points apart
P/E
ADMA16.6
TMO36.8
TMO is 2.2 times ADMA
Dividend yield
ADMA0.0%
TMO0.3%
0.3 points apart
5-year return
ADMA+724.1%
TMO+11.8%
712.3 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
ADMA+724.2%
TMO+11.8%
| Period | ADMAWith dividends | TMOWith dividends |
|---|---|---|
| 1 year since November 12, 2025 | -16.9%Price -16.9% | +19.5%Price +19.1% |
| 3 years since November 13, 2023 | +265.8%+54.1% a yearPrice +265.8% | +58.8%+16.7% a yearPrice +57.3% |
| 5 years since November 12, 2021 | +724.1%+52.5% a yearPrice +724.1% | +11.8%+2.3% a yearPrice +10.2% |
| 10 years since November 15, 2016 | +116.1%+8.0% a yearPrice +116.1% | +384.5%+17.1% a yearPrice +371.0% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
ADMAADMA BiologicsTMOThermo Fisher Scientific
| Price | $13.68 | $700.22 |
|---|---|---|
| Market value | $3.0B | $260B |
| Enterprise value (EV) | $3.1B | $295B |
| P/E | 16.6 | 36.8 |
| P/E, 5-year median | – | 32.7 |
| P/B | 6.9 | 4.8 |
| EV/EBIT | 12.9 | 34.9 |
| Free cash flow yield | 4.4% | 2.9% |
| Revenue, 12 months | $519M | $47.4B |
|---|---|---|
| Net income, 12 months | $182M | $7.1B |
| Free cash flow, 12 months | $133M | $7.6B |
| Earnings per share, 12 months | $0.77 | $18.96 |
| Revenue growth, year on year | 19.6% | 3.9% |
| Revenue growth a year, past | +64.6%over 5 years | +6.7%over 5 years |
| EPS growth a year, past | – | +2.1%over 5 years |
| Gross margin | 68.5% | – |
|---|---|---|
| Operating margin | 46.5% | 17.9% |
| Net margin | 35.1% | 14.9% |
| ROIC | 32.6% | 8.2% |
| ROE | 42.5% | 13.4% |
| Cash | $125M | $6.1B |
|---|---|---|
| Total debt | $203M | $41.4B |
| Net debt / EBITDA | 0.3 | 3.7 |
| Interest cover | 22.8× | 5.5× |
| Dividend yield | – | 0.3% |
|---|---|---|
| Dividend per share, 12 months | – | $1.84 |
| Dividend growth a year, past | – | +14.3%over 5 years |
| Buyback yield | 1.1% | 1.2% |
| Shareholder yield | 1.1% | 1.4% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Thermo Fisher Scientific ($260B) is about 85.7 times ADMA Biologics ($3.0B), at today's prices.
Since November 15, 2016, ADMA's price moved +116.1% and TMO's +371.0%. With dividends: ADMA +116.1% (+8.0% a year), TMO +384.5% (+17.1% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for ADMA Biologics and 0.26% for Thermo Fisher Scientific. Over the last twelve months they paid – and $1.84 per share.
At today's price, the P/E is 16.6 for ADMA and 36.8 for TMO. It is the share price over the last twelve months' earnings per share.
Over the last twelve months, the net margin was 35.1% for ADMA Biologics and 14.9% for Thermo Fisher Scientific, and the operating margin 46.5% and 17.9%. Revenue was $519M and $47.4B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.